enVVeno Medical Corporation is a medical device company that develops bioprosthetic tissue based solutions for the treatment of venous disease. The company focuses on chronic venous insufficiency specifically affecting the deep venous system of the leg. Its lead products include the surgical VenoValve and the investigational transcatheter enVVe System both designed to replace faulty venous valves. enVVeno Medical Corporation operates a leased manufacturing facility in Irvine California that is ISO 13485 2016 certified for the design development and production of implantable medical devices. The firm aims to address a significant unmet need in venous care by offering a valve replacement that restores normal blood flow toward the heart.

enVVeno Medical Corporation has not yet generated product revenue because its VenoValve and enVVe System remain in development and regulatory review stages. The company incurred expenses related to research development preclinical testing and regulatory interactions with the U S Food and Drug Administration. Future revenue will depend on obtaining premarket approval for the enVVe System and subsequent commercial sales to healthcare providers. At present the firm does not have any marketed products or licensing income.

enVVeno Medical Corporation occupies a pioneering position in the venous valve market as there are currently no approved surgical or non surgical replacement venous valves for deep venous insufficiency. The company states that no effective treatments exist for deep venous CVI caused by incompetent valves which creates a relatively open field for its novel approach. Competitive advantages include a proprietary tissue processing and manufacturing methodology that eliminates recipient immune responses and ensures sterility. The firm holds forty two patents globally with nine issued by the United States Patent and Trademark Office protecting its vascular valve technologies. Its experienced management team and scientific advisory board bring expertise from previously approved medical devices. The company’s ISO certified facility in Irvine supports research prototype fabrication and current good manufacturing practices for Class III implantable devices. These factors together distinguish enVVeno from other players in the broader vascular device sector.

enVVeno Medical Corporation intends to sell its products to hospitals and healthcare providers that treat patients with severe chronic venous insufficiency. The anticipated customer base includes vascular surgeons interventional radiologists and interventional cardiologists who perform venous interventions. The company does not disclose specific customer names in the filing but indicates that its devices will be used in clinical settings where valve replacement procedures are performed. By targeting specialists who treat advanced venous disease the firm aims to establish adoption among physicians managing the most challenging cases of venous insufficiency.